Introduction
Myelodysplastic syndrome with myelofibrosis (MDS-MF ( þ )) is relatively uncommon, with an incidence of 11-17% of total MDS. [1] [2] [3] [4] [5] [6] Compared to MDS-without MF (MDS-MF (À)), MDS-MF ( þ ) is characterized by the following hematologic features (Sultan C et al. Acta Haematol 1987; 78: 91-93; abstract) [1] [2] [3] [4] [5] [6] [7] [8] [9] : (1) marked fibrosis of bone marrow; (2) increased numbers of small hypolobulated megakaryocytes in the bone marrow; (3) modest or absent visceral enlargement; (4) poor prognosis due to high incidence of bone marrow failure.
The mechanism underlying myelofibrosis has been reported to be the excess production of transforming growth factor-b (TGF-b) by CD34 þ cells, 10 monocytes 11 and megakaryocytes 12 in idiopathic myelofibrosis (IMF), by megakaryoblasts in acute megakaryoblastic leukemia 13 and by megakaryocytes in chronic myelogenous leukemia. 14, 15 In IMF, in addition to TGF-b, basic fibroblast growth factor (basic FGF) from megakaryocytes and platelets is also known to contribute to myelofibrosis. 16 However, the etiology of myelofibrosis and increased bone marrow megakaryocytes in MDS-MF ( þ ) is unclear.
We have previously reported that in both healthy volunteers (HV) and in patients with idiopathic thrombocytopenic purpura (ITP), 17 TGF-b1 regulates megakaryopoiesis by a negative feedback mechanism, but in essential thrombocythemia (ET), patients escape from this regulation through impaired Smad4 signaling. 18 Based on these previous observations, in the present investigation, we postulated that in MDS-MF ( þ ), TGF-b1 produced by blasts and megakaryocytes may increase the production of thrombopoietin by bone marrow stromal cells, which is responsible for megakaryocytosis, and the myelofibrosis may be ascribed to the activity of TGF-b1 from blasts and the increased megakaryocytes.
Materials and methods

Study subjects
This study was performed in accordance with the institutional review boards of Sapporo Medical University School of Medicine. Patients seen in the period 1997-2005 were enrolled after strict written informed consent. Study subjects included those with MDS-MF ( þ ), MDS-MF (À), IMF, ET, ITP, nonHodgkin's lymphoma (NHL) and HV. To quantitatively measure TGF-b expression (mRNA) in blasts of MDS-MF ( þ ), which were not obtainable from fibrotic bone marrow, we enrolled RAEB or RAEB in transformation (RAEB-t) patients for the study of both this disease and for the control disease, MDS-MF (À). Patients with acute myelogenous leukemia (AML) were also enrolled, but only for assessment of plasma TGF-b1 concentration. Patients with MDS and AML were classified according to FAB criteria 19, 20 on the basis of peripheral blood and bone marrow smears since WHO criteria may have classified four of our cases (two MDS-MF ( þ ) patients and two MDS-MF (À) patients by FAB classification) as AML and unable to be scored by IPSS.
Histological studies of bone marrow
Histological studies were performed on paraffin-embedded bone marrow trephine biopsies using hematoxylin and eosin (H-E), silver impregnation for reticulin and Mallory-Azan stain for collagen. The score of myelofibrosis was graded using the scoring system described by Manoharan et al.
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Enzyme-linked immunosorbent assay (ELISA) of plasma TGF-b1 and TPO Immunohistochemical staining of bone marrow trephine for TGF-b and CD61
We performed bone marrow immunohistochemical staining of TGF-b using the mouse TB21 anti-human TGF-b-specific antibody (Chemicon, Temecula, CA, USA) as described previously. 23 The intensity of TGF-b immunostaining in the sections was assessed by using an AxioCam photomicroscope and the KS-400 image analyzing system (Carl Zeiss Vision GmbH, Hallbermoss, Germany), following a previously reported method. 24 Bone marrow sections were also immunostained with the Y2/51 antiplatelet glycoprotein IIIa antibody (CD61) (Zymed Laboratories, San Francisco, CA, USA) according to the method by Cordel et al.
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Real-time RT-PCR for TGF-b1 mRNA of peripheral blood mononuclear cells (PBMNC) and CD34 þ cells
Since we could not aspirate a sufficient number of the cells which contain the blasts from the bone marrow because of myelofibrosis in MDS-MF ( þ ) patients, we analyzed the TGF-b1 mRNA expression of the PBMNC and peripheral blood CD34 13, 26, 27 Examination of megakaryocyte number and morphology in bone marrow trephines
We analyzed the number and morphological characteristics of megakaryocytes using bone marrow trephines stained with routine H-E. The number of megakaryocytes was counted per high-power field (HPF/400-fold magnification, being equivalent to 0.39 mm 2 ) in all fields available (410 fields per patient).
Cytokines
Recombinant human TPO was kindly provided by Kirin Brewery Co, Ltd (Tokyo, Japan). Recombinant human TGF-b1 in its active form was purchased from Genzyme Corp (Boston, MA, USA).
Colony-forming unit magakaryocyte (CFU-Meg) assay CFU-Meg assay was performed in the presence or absence of TGF-b1 following a previously reported method. 18 
Statistical analyses
The values for each of the measured variables are given as mean values7standard deviation (s.d.). Mean and s.d. were assessed using the Student's t-test. The Spearman's rank correlation coefficient was used to determine the relationship between the two data. A P-value of less than 0.05 was accepted as statistically significant.
Results
Demographics of patients and HV
Demographics of patients and HV are given in Table 1 . All MDS-MF ( þ ) patients were primary MDS but not therapyrelated MDS due to previous radio-chemotherapy. All cases with MDS-MF ( þ ) showed pancytopenia and absence of organomegaly. Peripheral blood showed trilineage dysplasia in MDS-MF ( þ ) and MDS-MF (À) patients. There were no differences between MDS-MF ( þ ) patients and MDS-MF (À) patients in IPSS score. 28 All MDS-MF ( þ ) patients died within 12 months from diagnosis from causes related to pancytopenia (patients 1, 2, 5, 6, 7) or from overt leukemia (patients 3 and 4). These patients' clinical and laboratory findings were compatible with acute myelodysplasia with myelofibrosis reported by Sultan et al. 7, 8 Since all patients with MDS-MF ( þ ) were either RAEB or RAEB-t according to the FAB classification of MDS, patients with RAEB or RAEB-t were included as the control population of MDS-MF (À) patients. There was no statisitically signifiicant difference in mean age among the disease groups. There were no differences in the percentage of bone marrow blasts, the counts of PB blasts, PBMNC or PB CD34
þ cells between patients with MDS-MF ( þ ) and MDS-MF (À). The PBCD34 þ cells count in IMF patients was significantly increased compared to those of MDS-MF ( þ ) (Po0.01) and MDS-MF (À) patients (Po0.01). The incidence of abnormal karyotype in bone marrow cells was more frequent in MDS-MF ( þ ) compared to MDS-MF (À).
Fibrosis grade of bone marrow
In the bone marrow of seven patients with MDS-MF ( þ ) (eight specimens) and three patients with IMF, bone marrow fibrosis with increased reticulin fibers and collagen fibers, corresponding to a 2 þ to 4 þ grade on the Manoharan scoring system, 21 were observed (Table 1, Figure 1 ). The evaluation was not possible for HV since informed written consent could not be obtained for a marrow trephine biopsy; no fibrosis was seen in the marrow trephines from patients of other diseases.
The number and morphological characteristics of megakaryocytes in patients 
Plasma concentrations of TGF-b1 in patients and HV
Although we initially intended to measure the TGF-b1 concentrations in the bone marrow to explore the possibility that TGF-b1 may be involved in the pathogenesis of myelofibrosis in MDS-MF ( þ ), a sufficient amount of the bone marrow fluid was not obtainable because of the myelofibrosis. Therefore, we measured the total TGF-b1 and active TGF-b1 in the peripheral blood of the patients (Table 2 ) following the previous notion that there is a positive correlation between the TGF-b1 concentration in bone marrow and the TGF-b1 concentration in peripheral blood. 22 Both total and active TGF-b1 were significantly elevated in MDS-MF ( þ ) compared to patients with other diseases or HV. They were also significantly elevated in IMF and ET when compared to MDS-MF (À), ITP, NHL, AML patients or HV.
Correlation between the plasma TGF-b1 concentrations and degree of myelofibrosis or number of marrow megakaryocytes in MDS-MF ( þ ) patients
There was a positive correlation (Y ¼ 78 þ 77X, r ¼ 0.824, P ¼ 0.023) between plasma-active TGF-b1 concentrations and the degree of myelofibrosis in MDS-MF ( þ ) patients. We then examined the relationship between the active TGF-b1 concentration in the blood vs the number of megakaryocytes in the bone marrow of MDS-MF ( þ ), comparing to those in MDS-MF (À)
patients. There was a positive correlation (Y ¼ À149.432 þ 23.964X, r ¼ 0.940, P ¼ 0.002) between the plasma-active TGF-b1 and the number of megakaryocytes in the bone marrow of the MDS-MF ( þ ) patients, while no such correlation was seen in the MDS-MF (À) patients. We did not study the correlation between plasma-active TGF-b1 concentrations and the degree of myelofibrosis or megakaryocyte number in IMF since there were only two patients whose plasma-active TGF-b1 concentrations were measured.
Correlation between the number of marrow megakaryocytes or blasts and degree of myelofibrosis in MDS-MF ( þ ) patients TGF-b1 mRNA expression in PBMNC or CD34 þ cells from MDS-MF ( þ ), MDS-MF (À) and IMF patients
We then analyzed the TGF-b mRNA in PBMNC by real-time RT-PCR. Since the amount of CD34 þ cells which contained many blasts left after in vitro sensitivity assay to TGF-b1 was insufficient for the present analysis in three of five MDS-MF ( þ ) patients and three of five MDS-MF (À) patients, we first measured TGF-b mRNA of CD34 þ cells only in the remaining two patients for each disease. In patients 1 and 7 of MDS-MF ( þ ), TGF-b mRNA levels of PBCD34 þ cells were higher than those in patients 2 and 3 of MDS-MF (À) and those of CD34 À cells in both MDS-MF ( þ ) and MDS-MF (À) patients (Table 3) . In other patients, we next compared the TGF-b mRNA levels of PBMNC since the absolute numbers of blasts in peripheral blood were not statistically different between MDS-MF ( þ ) and MDS-MF (À). Similarly, the TGF-b1 mRNA levels were significantly higher in the PBMNC of MDS-MF ( þ ) patients than in the PBMNC or BMMNC of MDS-MF (À) patients or the PBMNC of HV. In IMF patients, though there were only two cases, TGF-b mRNA levels of PBCD34 þ cells were apparently lower than those of MDS-MF ( þ ) patients, while TGF-b mRNA levels of PBCD34 À cells were higher than those of MDS-MF ( þ ) patients.
Immunostaining intensity of TGF-b of bone marrow cells in MDS-MF ( þ ), MDS-MF (À) and IMF patients
To validate that blasts in bone marrow of MDS-MF ( þ ) were indeed producing TGF-b1, as was found with peripheral blasts, we immunostained the specimen of bone marrow biopsy for TGF-b1 and CD61. Figure 2 shows a representative example of the staining patterns seen in one MDS-MF (À) patient (patient 3) (Figure 2A Degree of myelofibrosis in MDS-MF ( þ ) patients. Gitter staining for reticulin fiber (a) and Mallory-azan staining for collagen fiber (b) of bone marrow trephine biopsy specimen in MDS-MF ( þ ) patients. The reticulin content and presence or absence of collagen among the reticulin fibers were graded using scoring system described by Manoharan et al (1979) . Table 2 Plasma concentration of TGF-b1 
Correlation between the plasma TPO concentration and the number of megakaryocytes in patients and HV
To explore the possibility that the increment of megakaryocytes in MDS-MF ( þ ) may be ascribed to the activity of TPO, we assessed the plasma TPO concentrations in this disease comparing to those of other diseases and HV; the highest concentration was found in MDS-MF ( þ ) (132.3721.5 pg/ml) and was significantly higher than in IMF (78.1 pg/ml (patient 1), 70.9 pg/ml (patient 3)), ET (63.2717.4 pg/ml), ITP (38.177.0 pg/ ml), MDS-MF (À) (28.477.0 pg/ml), NHL (24.474.8 pg/ml) or HV (19.977.3 pg/ml). We then assessed the relationship between plasma TPO concentration and the number of megakaryocytes in the bone marrow of MDS-MF ( þ ) and MDS-MF (À), and we found a positive correlation in the former disease (Y ¼ 11.455 þ 6.132X, r ¼ 0.927, P ¼ 0.003) while no such correlation was seen in the latter disease. We did not carry out similar analysis on IMF for the same reason described earlier.
Correlation between concentrations of plasma active TGF-b1 and plasma TPO in MDS-MF ( þ ) and MDS-MF (À) patients
To address the possibility that high plasma TPO concentrations in MDS-MF ( þ ) reflected the increased TPO production in bone marrow stromal cells by stimulation of excessive TGF-b1 as proposed by us previously, 22 we examined the correlation between active TGF-b1 concentrations and TPO concentrations in circulation. There was a positive correlation between active TGF-b1 concentration and TPO concentration in the blood (Y ¼ À113.83 þ 3.301X, r ¼ 0.856, P ¼ 0.014) in MDS-MF ( þ ) while no such correlation was seen in MDS-MF (À).
Effect of TGF-b1 on TPO-induced CFU-Meg
To examine the sensitivity of megakaryocyte lineage cells to TGF-b we conducted a CFU-Meg assay of peripheral blood CD34 þ cells from MDS-MF ( þ ), MDS-MF (À) or IMF patients and bone marrow CD34 þ cells of ET patients or HV. The CFU-Meg of MDS-MF ( þ ), MDS-MF (À), IMF and HV were Table 3 TGF-b1 mRNA expression in peripheral blood mono- We analyzed the TGF-b1 mRNA expression of the CD34 + and CD34 À mononuclear cells in peripheral blood. A real-time quantitative assay was performed as discribed in Material and methods. The final relative TGF-b mRNA expression level was expressed as (TGF-b1/GAPDH mRNA ratio) (log). Two PBMNC samples from patients 1 and 7 with MDS-MF(+), two PBMNC samples from patients 2 and 3 with MDS-MF (À) and two PBMNC samples from patients 1 and 3 with IMF were assayed. Assays were not possible due to insufficient material available for all other patients and HV, while patient 2 with IMF was already deceased at the time of the study, and no stored samples were available. We also analyzed the TGF-b1 mRNA expression of the mononuclear cells in peripheral blood and bone marrow. Five peripheral blood mononuclear cell (PBMNC) samples from patients 1, 2-(2), 3, 6 and 7 with MDS-MF (+) were assayed. Assays were not possible for patients 2-(1) and 5 due to insufficient material, while patient 4 was already deceased at the time of the study, and no stored samples were available. The assays were conducted on five PBMNC samples from patients 1, 2, 3, 4 and 7 with MDS-MF(À), and four bone marrow mononuclear cell (BMMNC) samples from patients 1, 2, 3 and 7 with MDS-MF (-), and four PBMNC samples from HV 1, 2, 3 and 4. Assays were not possible due to insufficient material available for all other patients and HV. *Po0.05.
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almost completely suppressed by TGF-b1 at a concentration of 1.0 ng/ml (Figure 3 ). On the other hand, CFU-Meg of ET patients was less sensitive to TGF-b1 than that of MDS-MF ( þ ) patients or HV (Po0.01).
Discussion
In the present study, we indicated that both myelofibrosis and megakaryocytosis in MDS-MF ( þ ) are primarily ascribed to active TGF-b, which is released from blasts. The involvement of TGF-b from blasts in myelofibrosis was suggested by the following observations: (1) In IMF patients, plasma-active TGF-b1 concentrations were lower than those of MDS-MF ( þ ) patients and yet the grade of myelofibrosis was similar to those of MDS-MF ( þ ) patients. Therefore, as described by Martyre et al, 16 not only TGF-b, which may be derived from megakaryocytes, CD34 þ cells and monocytes in CD34 À fractions in peripheral blood, but also the other fibrogenic cytokines such as basic FGF, was surmised to be involved in the myelofibrosis in patients with IMF.
Since the number of magakaryocytes were increased in the bone marrow of MDS-MF ( þ ) to a greater degree than in MDS-MF (À), though the immunostaining intensity of TGF-b in each megakaryocyte was almost the same in these disorders, the total amount of TGF-b in bone marrow released from the increased megakaryocytes may be increased and thereby may also be responsible for myelofibrosis. This assumption is compatible with the recent observations that IMF 29 and mice with transplanted bone marrow transduced with the TPO gene 30 had increased bone marrow megakaryocytes produced by high concentration of TPO, resulting in the overproduction of TGFb1, which brings about myelofibrosis.
With regard to the mechanism of the increment of megakaryocytes in MDS-MF ( þ ), the malignant nature of megakaryocytes per se may be one possibility, but more plausible, or an additional possibility, is that TPO released from stromal cells, which were stimulated by TGF-b from blasts may play a role. The latter possibility was deduced from the facts that plasma TPO levels were increased in MDS-MF ( þ ) compared to those in MDS-MF (À) and HV, the number of megakaryocytes correlating with the levels of TPO in MDS-MF ( þ ), and our previous notion that the production of stromal TPO increases in Tables 1, 3 and 4) (C). White arrow, megakaryocytes; small black arrow in A and B (green arrow on the HTML version) blasts; large black arrow in C (red arrow on the HTML version) small mononuclear cells considered as CD34 þ cells; White arrow head, monocyte. Table 4 Intensity of TGF-b immunostaining in bone marrow megakaryocytes and nonmegakaryocyte cells response to TGF-b. 22 Further, the observation that plasma TPO levels did not inversely correlate with platelet counts (data not shown) denies the sponge theory, 31 which proposes the regulatory role of platelets in plasma TPO levels, and also supports the latter possibility.
As to the hypolobularity and smallness of the megakaryocytes' size, they may also be ascribed to the function of TGF-b. We have previously disclosed that in ITP, maturation of megakaryoblasts was inhibited by TGF-b released from destroyed platelets at the mid-megakaryocytic stage, 22 exhibiting an increased number of small hypolobulated megakaryocytes in bone marrow while in ET, increased megakaryocytes in bone marrow were hyperlobulated and large sized, reflecting the fact that CFU-Meg in this disease was not sensitive to suppression of TGF-b. The result of the present study on the effect of TGF-b on CFU-Meg clearly indicates that unlike ET but similarly to ITP, megakaryoblasts of MDS-MF ( þ ) and IMF are sensitive to TGF-b, suggesting that maturation of megakaryoblasts may be inhibited when TGF-b levels are high. However, these abnormal features of megakaryocytes, hypolobularity and smallness in size may simply reflect the malignant nature of MDS-MF ( þ ) since they are generally found with other types of MDS. The mechanism underlying these abnormal features thus remained unsolved in the present study, and should be clarified by a future study.
In this study, we examined only RAEB or the RAEB-t subtype of MDS, from which we were able to recover peripheral blasts, and excluded other types, RA, RARS and CMMoL, because we needed a number of blasts which were not obtainable from the bone marrow of myelofibrosis for analysis of TGF-b expression. Therefore, issues also remain unclear such as whether the TGF-b from blasts in the excluded subgroups, which have a relatively small number of blasts in bone marrow compared to RAEB or RAEB-t, are also playing a role in myelofibrosis and whether megakaryocytosis in these subtypes are due to TPO from stromal cells primed by TGF-b even in these subgroups; it may be reasonable, however, to speculate that the increase of megakaryocytes are at least partly responsible for fibrosis as megakaryocytes are known to produce large amounts of TGF-b in a mainly pathophysiological status. 22 Nonetheless, direct proof of our present notion that increased production of TGF-b by blasts is involved in myelofibrosis and megakaryocytosis in RAEB or RAEB-t will require a demonstration that treatment to decrease blasts actually reduces myelofibrosis. In this context, a report by Takabayashi et al 32 who showed successful resolution of myelofibrosis in an MDS-MF case with an intermediate dose of cytosine arabinoside is quite supportive of our notion.
For conclusive elucidation on the therapeutic effects, however, future studies dealing with a greater number of cases are certainly warranted. þ cells from HV (&), ET patients ( ), MDS-MF (À) patients ( ) and IMF patients (J) were cultured in a 35-mm diameter plate in the presence of different concentrations of TGF-b1 (0.1 or 1.0 ng/ml) and recombinant human TPO (100 ng/ml) in a-MEM containing 20% fasting plasma from a healthy volunteer and 0.8% methylcellulose. The vertical axis shows the ratio of colony number (TGF-b1-treated colony number/TGF-b1 nontreated colony number). Four samples, one from each of patients 1, 2-(2), 3 and 6 with MDS-MF ( þ ) were assayed. Assays were not possible for patient 2-(1) and patient 5 due to insufficient material, while patient 4 was already deceased at the time of the study, and no stored samples were available. One sample from patient 1 with MDS-MF (À), four samples from HV, two samples from IMF and four samples from ET were assayed. Assays were not possible due to insufficient material available for all other patients. n Po0.05.
TGF-b produced by blasts promote the myelofibrosis in MDS
T Akiyama et al
